C&CURE & ADVANCEMENTS
Cure & Advancements/November 18, 2026/2 min read

Breakthrough T1D Gala Raises Millions to Advance Type 1 Diabetes Research

The organization's 53rd annual New York City Promise Gala brought together the T1D community to support clinical trials and emerging treatments. Celebrity host Este Haim, who lives with T1D, highlighted the gala's role in moving research toward new possibilities.

Research summaryNews report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

  • Breakthrough T1D's Promise Gala has raised over $85 million across five decades to fund T1D research and clinical trials
  • Funds support grants that help move potential treatments from research into human trials
  • GRAMMY-nominated musician Este Haim, diagnosed with T1D at age 14, served as emcee and emphasized the importance of research funding
  • Clinical trials funded by the organization are exploring new treatment approaches, including cell therapy

A Flagship Event for T1D Philanthropy

On November 18, 2026, Breakthrough T1D held its 53rd Annual New York City Promise Gala at the historic Plaza Hotel. The event brought together members of the Type 1 diabetes community and supporters to advance research funding during National Diabetes Awareness Month.

Over five decades, the Promise Gala has become one of New York's signature philanthropic events, raising more than $85 million to date. The gala was co-chaired by Allison Aston and Bonnie Bergstein, with Jim Nadler serving as corporate chair and Christopher Evans as fundraising chair.

From Research to Clinical Trials

Funds raised at the Promise Gala support a critical bridge in Type 1 diabetes research: grants that help move promising scientific discoveries into clinical trials. These trials test potential treatments in people, bringing new approaches closer to real-world availability.

The organization's investment strategy focuses on advancing multiple research pathways simultaneously, recognizing that different approaches may benefit different people with T1D.

A Voice for the Community

GRAMMY-nominated musician Este Haim served as emcee for the 2026 gala. Haim was diagnosed with Type 1 diabetes at age 14 and has managed the condition daily while pursuing her career as a musician, composer, actor, and writer.

"Hosting the Breakthrough T1D Promise Gala is a chance to celebrate the T1D community and raise funds that will help push research toward cures for type 1 diabetes," Haim said. Her involvement underscores how people living with T1D are central to the organization's mission and advocacy efforts.

Real Impact in Clinical Settings

The gala's fundraising has tangible outcomes. Clinical trials supported by Breakthrough T1D funding are exploring innovative treatment approaches, including cell therapy. These trials are testing whether new methods can reduce or eliminate the need for insulin in people with Type 1 diabetes.

While clinical trials represent an important step toward advancing treatment options, they also demonstrate the organization's commitment to translating basic research into potential therapies that may one day transform life with T1D.

Evidence label

Origin: prnewswire.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.